NDA/BLA filedconf 0.80

relacorilant — NDA/BLA filed

$CORT · CORCEPT THERAPEUTICS INC · hypertension secondary to hypercortisolism

Event date

Date TBD

Sponsor runway

5+ yrs

$338.2M liquid

Evidence

“the Company has submitted a new drug application to the U.S. Food and Drug Administration for its proprietary, selective cortisol modulator, relacorilant, to treat patients with endogenous hypercortisolism (Cushing's syndrome)”

Source: 8-K filed 2024-12-30View on EDGAR ↗0001193125-24-286917

Comparable historical nda/bla fileds· last 5 years · same indication

Ticker	Drug	Date	Outcome
$CORT	relacorilant	2025-03-03	unknown

Recent insider activity· ±90 days

3 insiders · 0 buys · 2 sells

Gift

2026-05-13

Robb Gary Charles

Chief Business Officer

5,300 @ ——

Gift

2026-05-13

Robb Gary Charles

Chief Business Officer

1,000 @ ——

Exercise10b5-1

2026-05-05

Guyer William

Chief Development Officer

20,000 @ $21.65$433K

Sell10b5-1

2026-05-05

Guyer William

Chief Development Officer

20,000 @ $51.83$1.04M

Sell10b5-1

2026-05-01

BELANOFF JOSEPH K

Chief Executive Officer

40,000 @ $50.10$2.00M

Date	Insider	Action	Shares	Price	Value
2026-05-13	Robb Gary CharlesChief Business Officer	Gift	5,300	—	—
2026-05-13	Robb Gary CharlesChief Business Officer	Gift	1,000	—	—
2026-05-05	Guyer WilliamChief Development Officer	Exercise10b5-1	20,000	$21.65	$433K
2026-05-05	Guyer WilliamChief Development Officer	Sell10b5-1	20,000	$51.83	$1.04M
2026-05-01	BELANOFF JOSEPH KChief Executive Officer	Sell10b5-1	40,000	$50.10	$2.00M

← All catalysts for $CORT